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Introduction 
Bleeding disorders are said to affect 1 out of 1,000 men and women all over the world 
(1). Hemophilia A and Von Willebrand Disease amongst them rank as the most 
common(2,3).  Indian data are maintained  by the HFI (Hemophilia Federation of India). 
As per data  that was released in 2011 , 14,718 patients who presented with bleeding 
disorders  11,586  patients  were patients of  Haemophilia A. (4)India reports  third 
largest number of patients with bleeding disorders , and also the second highest number 
of patients having  Haemophilia A .(4)  Other bleeding disorders include the rare factor 
deficiencies and Platelet function disorders. RBDs are reported in almost all populations, 
incidence varies from 1 out of 500 000 for deficiency of Factor VII  to 1 in every 2 to 3 
million for deficiency of Factor II and  Factor XIII .(5,6)  The incidence of inherited 
platelet function disorders are much lower as compared to other bleeding disorders.(7) 
 
Given the prevalence and the morbidity associated with bleeding disorder, proper 
diagnosis and early management will give the patients a better quality of life. While 
diagnosing severe bleeding disorder may not be problematic, diagnosing mild bleeding 
disorder remains a challenge.(8) Adding to the challenge is the fact that  severity of 
bleeding disorder is highly subjective and studies have shown that even healthy 
volunteers when asked for the presence of bleeding symptoms answer in the affirmative, 
that was as high as  65 % in females and 35 % in males(9). Hence it is important to ask 
precise guided questions that will help us arrive at a better conclusion. With the 
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importance of a well taken history in the diagnosis of bleeding disorder in mind and in an 
attempt to standardize bleeding history many bleeding assessment tools(BAT) have been 
introduced.  Standardized questions in combination with an  interpretation grid, which is 
well defined and used  for finally computing the bleeding score is referred to as BAT.(10)  
In 1995 Sramek et al published their findings and in 2005 International Society on 
Thrombosis and Hemostasis(ISTH) set  out a provisional criteria for diagnosis of Von 
Willebrand Disease.(10,11)  
 
Building on this criteria investigators from Vicenza Italy developed and validated a 
questionnaire in 2005, to improve the sensitivity of the bleeding score further  
two different bleeding assessment tool by the name European Molecular and  
Clinical Markers for the Diagnosis and Management of type 1 VWD (MCMDM-1  
VWD) was developed but owing to its long administration time a shortened version of 
the same was developed. In order to develop a consensus bleeding score by combining 
the results obtained from all the  assessment tools mentioned above ISTH  published the 
ISTH- BAT in 2010.(12) The aim of our study is  to see the utility of ISTH-BAT in 
evaluation of hemostasis among patients who get referred to our laboratory for the same . 
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Rare bleeding disorders eludes  detection by routine coagulation tests  and  abnormality 
in these tests  do not always translate to clinical bleeding.(13) So it was decided  that as 
an adjunct to  BAT and other lab tests a global test of hemostasis  namely  
Thromboelastography (TEG)  would  be included in these patients.  The  limitations of 
test being routinely done for work-up of  a bleeding  patient  is that there are a number of 
tests each  evaluating a single  aspect of coagulation.  On the other hand global  assays of 
coagulation like TEG  measures the  effect of various deficiencies in coagulation while 
retaining the interactions of other components of blood like erythrocytes, platelets and  
leucocytes  as the test is done in whole blood. In contrast to other routine tests TEG offers 
information about all phases of coagulation.(13) 
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AIM:  
Determintion of  the clinical utility of Thromboelastography and ISTH BAT for 
evaluating  patients referred for complete coagulation work-up. 
 
OBJECTIVES: 
1) To calculate the sensitivity, specificity, positive predictive value (PPV) and 
negative  predictive (NPV) of ISTH  BAT  in evaluation of patients referred for 
complete coagulation work-up. 
 
2) To calculate the sensitivity, specificity, negative predictive value (NPV) and 
positive predictive value (PPV) of  Thromboelastography in patients referred for 
complete coagulation work-up. 
 
3) To calculate the sensitivity, specificity, negative predictive value (NPV) and 
positive predictive value (PPV) of Thromboelastography and ISTH BAT in 
patients referred for complete coagulation work-up. 
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HEMOSTASIS: 
The classical also sometimes referred to as the cascade based model of hemostasis 
describes series of reactions involving sequential activation of various clotting factors by 
one of the two pathways, either intrinsic or extrinsic pathway, the endpoint of these 
activation resulting in copious amount of thrombin generation and  the eventual 
conversion of fibrinogen to fibrin clot.(14)(Fig.1) 
Although this explanation supports laboratory investigations of hemostasis it is not very 
useful in understanding the events of hemostasis in-vivo.  The model also is incapable of 
explaining why some patients with factor deficiencies bleed while others with low levels  
of Factor XII and High molecular weight kininogen(HMWK) do not inspite of an APTT 
that is prolonged which would normally mean the defect in the intrinsic pathway.(15)This 
model also failed to explain that in haemophiliacs with normal PT , how is it that the 
normal extrinsic pathway fails to compensate for prolonged bleeding. 
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 Figure 1: Adapted from Maureane Hoffman. A cell-based model of coagulation ,Blood 
reviews 2003:17;51-55 
These questions necessitated the introduction of a  cell based model of hemostasis. This 
model emphasizes that coagulation in vivo occurs in three steps that occur on a surface of 
a cell, and these steps usually are overlapping.(15) 
The three phases are Initiation, Amplification and Propagation.(15) 
Initiation: This event takes place on the surface of cells that bear tissue factors. This may  
refer to the extrinsic pathway of the earlier model as  normally  tissue factor bearing cell 
remains outside of the vascular compartment, therefore extrinsic or outside to blood. 
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Although many cells may produce tissue factor it is only in the setting of inflammation,  
that they do come in contact with blood. However some evidences point to the fact that 
initiation of coagulation  in the extrinsic system occurs even in healthy individuals  all the 
time but coagulation is prevented as  the intact vessel wall creates a barrier of sorts 
between  tissue factor and other components of coagulation.(15) 
 
Amplification:  Vascular damage results in components of the vascular system  
previously unable to leave the vascular compartment owing to their large size to come 
out. Notable among these are platelets and Factor VIII and vWF. As they exit the vessel 
compartment they come in contact with  tissue factor  present on the surface of  cells that 
bear them. Platelets form a plug after attaching to these. The thrombin present activates 
the platelets and also activation of the clotting factors namely FVIII that ultimately helps 
in the cleavage of VWF. Factor XI also gets activated. This may explain why Factor XII 
is not essential in hemostasis . Though insufficient to form a clot by itself, thrombin that 
is present on the  tissue factor bearing cells surface  help in activating platelets that are 
now layered with co-factors which are procoagulant. The product is now ready for 
propagation. 
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PROPAGATION:  
During propagation, on the surface of activated platelets, Factor IXa combines with its 
cofactor Factor VIIIa on the surface of activated platelets. This complex then goes on to a 
to form Factor Xa, as a result of activation of FX.  The FXa then combines with its co-
factor. 
The Factor Xa /Va complex  then converts large amount of  fibrinogen to fibrin that helps 
in stabilization of the clot. The cell based model of coagulation thereby helps in better 
understanding of the mechanism than the earlier postulated  hypothesis,otherwise known 
as the cascade hypothesis.(16)  
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 Figure 2:Adapted from Maureane Hoffman. A cell-based model of  hemostasis . Blood 
reviews 2003:17;51-55 
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OVERVIEW OF COMMON AND RARE BLEEDING DISORDERS: 
1) Disorders of soluble clotting factor: The most common among these are classical 
Hemophilia or Hemophilia B due to deficiency of FVIII and FIX respectively. 
2)  Other disorders include: 
Fibrinogen Abnormalities: Normally pattern of inheritance being  autosomal recessive . 
Two forms known are Afibrinogenemia and Dysfibrinogenemia.(17) Fibrinogen is 
composed  three polypeptide chains, each with two sets: Aα, Bβ and γ, and when any of 
the chains are defective, it results in a rare bleeding disorder called Afibrinogenemia. The 
dysfibrinogens may be the result of one of the following mutations, missense, nonsense, 
or splice junction mutations.(18) 
Prothrombin (Factor II) Deficiency:  It is  one of the rare bleeding disorder and the 
pattern of inheritance is Autosomal Recessive . 
Factor V Deficiency:  It is an autosomal recessive condition caused by an abnormality in 
Factor V gene. More than 40 mutations have been described in Factor V gene, even then 
they are more common than the mutations seen in other clotting factors.(19) 
Factor VII Deficiency: An autosomal recessive disorder seen to occur in mild, moderate 
and severe forms. Factor VII  is the main initiator of clotting mechanism along with other 
co-factors. There are more than 100 mutations in the gene  identified so far.(19) 
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Hemophilia A and Hemophilia B  : These  conditions have a  unique pattern of 
inheritance, X linked recessive. Conversion of  pro-thrombin to thrombin is done by these 
two factors. They are of  mild moderate and severe forms.(18) Several hundred mutations 
have been identified.(19) 
 
Factor X Deficiency: Factor X deficiency also shows an autosomal recessive mode of 
inheritance.  It is also classified as mild, moderate severe and the symptoms    bear    
resemblance to  Hemophilia A.(18) 
 
Factor XI Deficiency: Bleeding in this disorder may be of varying severity, this is 
probably due to normal levels of Factor VIII and IX that  forms tenase complex and 
Factor V and X that  forms pro-thrombinase complex.(18) This exhibits AR mode of 
inheritance. 
 
 Factor XII deficiency, Prekallikrein and HMWK deficiency:  
Autosomal recessiveinheritence . Most patients come to notice because of incidental 
prolonged APTT. 
 
Factor XIII Deficiency:   Deficiency of plasma transglutaminase results in this particular 
disorder,  FXIII is required for cross-linking of  fibrin chains to form a clot of Fibrin that 
is impermeable.  2 A chains and 2 B chains together constitute FXIII,  A being   the 
active subunit, B  acts as a carrier for the A subunit. 
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Multiple Clotting Factor Deficiencies : Factor VIII and Factor V deficiency occur 
together. This is followed by combined deficiency of Factors II, IX,VII and X. Mode of 
inheritance being AR.(18) 
von Willebrand Disease :  Most common  amongst hereditary clotting factor deficiency. 
von willebrand factor  facilitates  platelet adhesion is a  carrier of clotting factor VIII.  
 
 
Table 1: Classification of vWD 
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INHERITED PLATELET DISORDERS:  
Bernard Soulier syndrome: It is one of the  syndrome that comprises the Giant platelet 
syndrome. This is an autosomal recessive condition and  affects one of the genes 
encoding the Gp Ib/V/IX complex. Fechtner, May Hegglin, Sebastian,Epstein are other 
macrothrombocytopenia syndromes that arise secondary to MYH9 gene. 
 
Glanzmann Thrombasthenia: This is caused by the defect in platelet membrane 
complex Gp IIb/IIIa. The defect may sometimes be seen in other gene, it exhibits 
molecular heterogeneity. 
 
Storage Pool Deficiency: ADP, ATP, calcium and serotonin are the contents of dense 
granules  whereas alpha granules  have  fibrinogen, FV, thrombospondin , platelet 
derived growth factor,fibronectin. Failure to release the contents of platelets on activation 
results in Storage pool deficiency.(18) 
Given the varied presentation of bleeding disorder and the inherent challenges in its 
diagnosis, the importance of well taken relevant history cannot be overemphasized. 
 
 
17 
 
 
Table 2: Features of  Inherited deficiencies of coagulation factors .(Adapted from  
)
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A  clear, correct and precise bleeding history is the most useful tool for diagnosing a  
bleeding disorder, based on the history further investigations should be decided. 
Diagnosing bleeding disorder especially in its milder forms pose a big challenge to the 
physicians as bleeding is a symptom found in healthy as well as diseased population. It 
has been seen that when people are merely asked for the presence or absence of bleeding 
disorder a high percentage of healthy people say yes, this shows the importance of a well 
taken history with guided questions in distinguishing pathological bleeding from normal 
bleeding. (9)  Attempts to standardize history taking in bleeding disorders have been 
going on and in the process many different types of bleeding assessment tools that are a 
set of questionnaire pertaining to bleeding episodes, severity and treatment received for 
the same  have been developed.(12). In 1995 the first bleeding assessment tool was 
developed and subsequently validated.(11) Thereafter  BATs have gone many evolutions 
and in 2010  ISTH  published  a  BAT(10). 
Vicenza based bleeding score: 
When ISTH first laid down the criteria for BAT a group of investigators that was lead by 
Rodeghiero developed a bleeding assessment tool for VWD  Type 1 , in this the bleeding  
symptoms present were given scores ranging from 0 to 3 and the final score were to be 
summated ,when this bleeding score was subsequently validated with a cut off score of 3 
for males and 5 for females the specificity for the disease was found to be  98% and 
sensitivity of  65%.(20). 
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To increase the sensitivity of BAT further revision of scoring system was done and a 
negative score for absent bleeding despite significant hemostatic challenge was 
introduced and the score now ranged from -1 to 4. This model was used for European 
Molecular and Clinical Markers for the Diagnosis and Management of type 1 VWD 
(MCMDM-1 VWD) Study.(21)  Owing to its long administration time the score was 
further shortened version of the same was introduced. This particular BAT was 
prospectively analyzed one in the setting of  primary care  and another in two groups of 
referred  population. In the setting of  primary care patients the questionnaire gave  a 
sensitivity of 100% and specificity of 87%, However in the  other set  the sensitivity and 
specificity obtained  was widely variable.(22,23). With a view of consolidating the 
knowledge that was acquired from all these published studies and the need for a 
consensus bleeding assessment tool , ISTH  established a scientific sub –committee(SSC) 
which with inputs received from women’s health issue SSC  published a questionnaire 
known as the ISTH BAT in 2010(10).  There is an ongoing attempt to validate this tool 
has been  and a web based version encouraging the researchers to share their data is 
available.(12) 
 
ISTH BAT 
ISTH BAT was developed and published by the ISTH SSC in 2010. The issues that led to 
the development of this tool was to establish a single bleeding assessment tool that would 
be useful for the standardization of  bleeding symptoms reporting  and would be useful in 
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adults and the pediatric population alike. The problems with the already existing BATs 
were that they were validated using the normal population as  a reference  so the chance 
of missing mild disorders were high and also because the primary focus was in the 
diagnosis of mild bleeding disorder(MBD) there was every chance of the score getting 
saturated in severe bleeding disorder. ISTH BAT was created to overcome these 
problems.(10). ISTH BAT has a score of 0 to 4 for each symptom and has a maximum 
score of  56 in females and 48 in males. A score of 3 in pediatric population, 4 and more 
in adult males and 6 and more in adult females are considered significant.(24)(ISTH BAT 
in annexure) 
Other bleeding assessment tools: 
Apart from the BATs developed by the Italian group various other BATs have been 
developed and published.(12) These include: 
Menorrhagia specific tools: 
Menorrhagia is an important hemostatic challenge and it is seen that of all the women 
who experience excessive bleeding symptoms 15% have an underlying bleeding 
disorder.(25) Menorrhagia also remains one of the most frequently reported bleeding 
symptom among women. Menorrhagia specific BAT involves a Pictorial Bleeding 
assessment chart (PBAC) which enables women to document the number of tampons ans 
sanitary napkins used and the extent of soiling on each, based on which  a score is 
obtained, score of 185 and more is considered significant.(12) 
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Figure 3a: PBAC , Menorrhagia specific tool. 
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Figure 3b: PBAC , Menorrhagia specific tool.(Scoring system) 
 
Pediatric bleeding assessment tools: 
While the diagnosis of mild and rare bleeding disorder is in itself very challenging, 
bleeding disorders in pediatric population pose a whole set of fresh challenges. The 
classical bleeding symptoms usually seen in adult population are usually lacking in 
children this combined with  the obvious absence of hemostatic challenge makes it 
further more difficult to know the bleeding symptoms. Some early symptoms like 
umbilical cord bleeding could have been overlooked or forgotten. Hence a specific BAT 
meant to overcome these challenges in pediatric population was warranted.(12) 
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Since ISTH endorsed Vicenza based BATs Bowman et al created a pediatric specific 
BAT by adding symptoms specific to pediatric population into MCMDM-1 VWD 
questionnaire. The pediatric bleeding questionnaire thus created and subsequently tested 
showed a sensitivity and specificity of  83% and 70 % respectively.(26) 
 
Composite clinical score for clinical severity of Hemophilia.: 
Plasma levels of Factor levels poorly correlates with phenotypic expression of 
Hemophilia (27) Assessment of probable factors that influence  phenotypic expression of 
Hemophilia has garnered considerable interest. Several Factors namely  half life of Factor 
VIII ,  Thrombin generation, vWF  and also the components of fibrinolytic systems have 
been evaluated.(28–31)  
Since there are several aspects of severity it was decided to construct a composite score 
for Hemophilia severity which may be useful. The items in the Hemophilia Severity 
Score were: 
1) Joint bleeds-annual incidence 
2)  Orthopedic joint score given by WFH 
3) Factor consumption per annum. 
They concluded that Hemophilia Severity Score was a  tool that was able to provide  
information about the clinical severity of Hemophilia in adults.(32) 
This scoring system was further validated by Tagliaferri et al ,where they found it to be a 
useful tool in assessing the phenotypic severity of Hemophilia. 
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Evaluating clinical utility: 
While evaluating the  BATs for its clinical utility the  objective and the setting where it is 
used   must be borne in mind. It may be used  for screening  patients during first visit  in 
primary and tertiary centers or it can be used in  assessing disease severity. Although the 
focus of Vicenza based BAT s have been VWD but many prospective studies have taken 
place to evaluate the clinical utility of BATs in evaluation of other bleeding disorders. 
(12)  Also while evaluating the clinical efficacy it is important to recognize how study of 
a particular population affects the results, for example if a known bleeder were to be  
enrolled into the study it would falsely  increase the sensitivity. Rodegheiro in 2005 
eliminated this problem by enrolling subjects who werev obligate carriers  of VWD 
rather than studying the   cases of the same.(33). Tossetto et al in 2006 considered only 
the symptoms present prior to the diagnosis of Type 1 VWD for calculating  the score  
whereas Bowman et al in 2006 with MCMDM 1 and PBQ used only the first time cases. 
Also the controls used in all were  healthy population.(21,22,26).  
While the clinical utility of Vicenza based BATs have mainly be done with respect to 
VWD several prospective studies analyzing its utility in other inherited bleeding 
disorders have been carried out. The Condensed MCMDM VWD Type 1 has been used 
for prospective evaluation of platelet function disorder with specificity, sensitivity, PPV 
and NPV  of 86%, 65%, 0.50 and 0.92 respectively(12). Tosetto et al in 2011 used the 
BAT for various bleeding disorder and found that there was heightened sensitivity when 
the bleeding score was used in conjunction with Activated partial thromboplastin 
time.(34) 
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ISTH BAT has also been evaluated for diseases other than VWD. Lowe et al 
prospectively analyzed  bleeding assessment tool in patients with inherited platelet 
disorder and concluded that though  for documentation of  bleeding symptoms, ISTH 
BAT was an effective  however the score thus obtained was not indicative of a platelet 
function disorder and there was no correlation  with the defect observed on platelet 
aggregometry. (35). 
 More recently in 2016 Rashid et al administered ISTH BAT in patient with Platelet 
function disorder in a  setting with resource constraint  and concluded that apart from 
being a very useful tool for documentation of bleeding symptoms over time   the BAT 
was also predictive of platelet function defect as eventually  identified by  aggregometry 
with odds ratio 3.25 [95% confidence interval 2.13-4.37, p = < 0.001](36) 
Kaur et al also evaluated the utility of ISTH BAT in platelet function disorder especially 
Glanzmann Thrombasthenia and Bernard Soulier Syndrome, they even compared the web 
version and the normal version and the result they obtained showed a sensitivity, 
specificity, PPV and NPV of ISTH BAT in platelet function disorder of 100%, 76.2%, 
0.9 and 1 respectively.(37) 
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TABLE 3: DEPICTS THE EVOLUTION OF VICENZA TYPE BLEEDING 
ASSESSMENT WITH ITS YEAR OF PUBLICATION AND THE RANGES: 
BAT and YEAR 
OF 
INTRODUCTION 
SCORING 
SYSTEM 
POSSIBLE 
RANGE OF 
SCORE 
ABNORMAL 
BLEEDING  
SCORE 
ADMINISTRATION  
TIME 
Vicenza bleeding 
questionnaire 
(VBQ) 
2005 
0 to + 3  
 BS of >3 in 
males and>5 
in females 
40 Minutes 
MCMDM1-VWD 
2006 
 
−1 to +4 –3 to +45 >4 40 Minutes 
Condensed 
MCMDM-1VWD 
BQ 
2008 
-1 TO +3 –3 to+ 45 >4 5 to 10 mins 
Pediatric Bleeding 
Questionnaire 
2009 
−1.5 to +2.5 -3 TO 48 
(BS) ≥2 
 
20 MINS 
ISTH BAT 
2010 
0 to 4 
 
0 to 48 in Men 
and children. 
0 to 56 in 
women 
BS of ≥4 for a 
Males, ≥6 for  
females and 
≥3for children 
20 MINS 
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VISCO ELASTIC TESTS:  
 Two major systems in place are using this technology  are Thrombelastograph (TEG) 
(Haemoscope Corporation, Niles,Illinois, USA) and the ROTEM (Pentapharm GmbH, 
Munich,Germany).(38) While the parameters measured by these machines are identical 
they differ in their primary mechanism. In TEG there is an oscillating cup that moves in a 
limited arc with sample inside and there is a pin/wire transduction system whereas in 
ROTEM the cup is immobile and pin transduction system oscillates. The analysis of TEG 
is called Thromboelastography whereas that of ROTEM is called Thromboelastometry.  
Both  ROTEM and  TEG come under a category of test called the test of global 
hemostasis.  Global tests of coagulation includes tests namely the  TEG, ROTEM and 
Thrombin generation test.(39) Traditionally hemostasis evaluation were being carried out 
by clotting times of plasma , APTT and prothrombin time (PT), these tests determine the  
conversion of  Fibrinogen to Fibrin that is dependent on thrombin and assesses only the  
clot formation initiation  and not the entire length of the process. This combined with the 
fact that these tests are performed at un-physiological conditions and these tests segregate 
coagulation into different compartments thereby precluding the study of other factors that 
impact coagulation process as a whole the conventional tests are riddled with 
limitations(40–42).   
At present, there is lack of easily available and standardized tests that can measure the 
hemostatis. Tests measuring global hemostasis can with greater sensitivity and accuracy 
capture  generation of thrombin and formation of Fibrin clot. These include thrombin 
generation assay(TGT), TEG and ROTEM.(43–45) 
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THROMBOELASTOGRAPHY: 
Thromboelastography/TEG is the method described by Dr Helmutt Hartert . The term 
refers  to the  obtained trace  as a result of viscoelastic changes produced during fibrin 
polymerization. TEG allows the evaluation of all the steps  of  hemostasis from initiation 
to formation and stability of clot.(39) As has been earlier mentioned that the TEG has a 
cup with a sample that rotates in a limited arc and there is a pin transduction system and 
the values are traced . The tracing thus obtained has the following parameters. .While the  
initial utility of TEG was meant to reduce transfusion requirement in complicated 
surgeries but now its utility has expanded to bleeding and thrombotic disorder.(39) TEG 
and its utility in bleeding disorder has also been greatly studied. 
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Table 4: Parameters measured by  TEG. 
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Figure 4: Normal tracing of TEG. 
TEG IN HEMOPHILIA: 
 Classical Hemophilia A and Christmas disease or Hemophilia  B are inherited deficiency 
of Factor VIII(FVIII) and Factor IX(FIX) respectively. Hemophilias are classified based 
on Factor levels into mild, moderate and severe. (Mild FVIII or FIX >5%, Moderate 1-
5%,Severe <1%). Even though considered rare,they are the most common when it comes 
to bleeding disorders. 
Traditionally diagnosis of Hemophilia and its monitoring has been based on  measurable  
levels of clotting factors in plasma. The advent of whole blood coagulation assay has 
meant that the whole dynamic process of coagulation is not compartmentalized and it can 
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be studied in an environment the interaction between enzymatic factors and platelet 
interaction is conserved.(46)   
In a study done by Chitlur_et al , where they studied 58 children with severe Hemophilia 
and their TEG profiling was done found that  the R time in children with Severe 
Hemophilia without inhibitors was significantly prolonged than the normal controls 
(p<0.001) and when they compared the time taken for clot formation in Severe 
Hemophilia A with inhibitors as against those without inhibitors, the R time was 
significantly prolonged in the former catergory.(p<0.001)The discrepancy often observed 
between phenotype and genotype in  severe Hemophilia A  have been studied and it was 
seen that patients who had less bleeding had better thrombin generation capacity(46). The 
utility of TEG in titration of recombinant FVII has also been evaluated.(44) 
TEG IN RARE BLEEDING DISORDERS: 
RBDs comprise of  coagulation factor deficiencies and platelet function defects. The 
inheritance of these disorders are usually AR.(47,48) Patients with RDB often have 
variable phenotypes that cannot be predicted by levels of clotting factors alone.(48,49).  
 
As is the inherent problem with all the coagulation tests commonly used that they 
compartmentalize the different facets of coagulation ,as a result RBD may evade 
detection by these conventional tests. Global coagulation assays  measure the effects of 
factor deficiency while the interactions of other factors like  Leucocytes, erythrocytes and  
Platelets intact.(13) 
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Zia et al studied TEG in the diagnosis of  RBDs. This was a retrospective study done on 
26 patients with rare bleeding disorder.  They had 4  patients of Fibrinogen deficiency, 1 
patient of pro-thrombin deficiency, 1 Factor V deficiency,3 patients of combined Factor 
VIII and Factor V deficiencies, 1 of Factor XI and 4 of Factor XIII deficiency. Other 
disorders included in the study were 1patient of PAI 1 deficiency, 1 of Vitamin K 
dependent clotting factor deficiency, 14 cases of Glanzmann Thrombasthenia  and 1 
patient of Bernard Soulier Syndrome. Apart from this there were 2 patients, 1 each of 
High Molecular Kininogen deficiency and 1 of FXII deficiency. (13) 
Fibrinogen Deficiency: 
TEG in these patients showed K time that was prolonged, and a decreased MA. 
Prothrombin deficiency 
Showed a prolonged R and K time. 
FV deficiency: 
Showed extremely prolonged R time and K time and reduced α angle. 
 FV + FVIII deficiency: 
This study evaluated 3 patients with combined factor V and VIII deficiency and along 
with prolonged R time and low normal MA. Another interesting observation in the study 
was that, that out of 3 patients two were siblings and had identical factor levels ,but one 
of the sibling was severely symptomatic while other was not. 
In the asymptomatic sibling it was found that she had less  prolongation of  
R time was less severe and normal K time., this pointed to the fact that TEG could predict 
bleeding phenotypes. 
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FVII deficiency: 
There were three patients of Factor VII deficiency identified in this study. Two out of 
three patients were severe bleeders and had markedly prolonged R and K time whereas 
the moderate bleeder among the three had lesser  degree of derangement. 
FXI deficiency: 
The Factor XI deficiency patient had  R time and K time both prolonged. 
FXII deficiency: 
TEG abnormality associated with FXII deficiency  R time that was prolonged . 
FXIII deficiency: 
When four patients of FXIII deficiency were evaluated TEG showed  low normal   MA 
and fibrinolysis. 
Glanzmann thrombasthaenia: 
Four patients with thrombasthenia revealed markedly decreased MA . 
Bernard Soulier Syndrome:  
Showed  increased K and decreased angle. 
PAI-1 deficiency: 
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Showed increased fibrinolysis. 
HMWK deficiency: 
The abnormality seen was  R time that was prolonged.  
While genetic testing may be confirmatory in rare bleeding disorders there is a poor  
correlation between genotype and phenotype.  There is also a lack of universal screening 
test for rare bleeding disorders. In a study done by Zia et al where they retrospectively 
analyzed 26 patients with rare bleeding disorders they found that TEG was abnormal in 
all 26 patients, the major limitation of this study was that it was retrospective in nature 
and owing to the rare nature of RBDs in general the small sample size and poor 
representation of some of the conditions a conclusive inference cannot be drawn. 
Nevertheless TEG may  be an effective screening tool for these  patients. (13) 
The heterogeneity of bleeding disorder makes it very cumbersome for practicing 
clinicians to diagnose these disorders accurately, added to that fact is the limitations of all 
the screening tests. Zia et al in their retrospective study found TEG to be of limited utility 
as a screening test for Inherited coagulation disorder. In their retrospective study they 
found that on 195 patients with 29 cases of diagnosed bleeding disorders that comprised  
TEG to have very poor sensitivity and specificity.(50) 
A  study has shown that when a BAT score is taken in conjunction with APTT, a normal 
BAT and a normal APTT  can  exclude the presence of a minor bleeding disorder(34) we 
decided to check the sensitivity and specificity of BAT score in conjunction with 
parameters of thromboelastography. 
35 
 
 
 
 
 
 
 
 
    
MATERIALS AND 
METHODS 
 
 
 
 
 
 
 
 
 
 
36 
 
MATERIALS AND METHODS 
 
This is a prospective  study done in the Department of Transfusion Medicine and 
Immunohematology, Special Tests Laboratory Christian Medical College and 
Hospital,Vellore,India. The study was approved by Institutional Review Board. 
A total of 223 patients who were referred for coagulation work-up in between November 
2015 and May 2016 were enrolled into this study. An informed consent was taken.All the 
patients who are referred to our lab for the said work-up undergo a set of tests based on 
the protocol of our lab. Before the sample for the test is taken registrars posted there take 
a detailed clinical history. For this study before the procedure began an informed consent 
and in case of children an informed parental consent and  a children assent was also 
obtained by the registrars. 
Patients referred to our lab mainly fall into one of the three categories. 
1. Patients referred for increased bleeding tendency. 
2. Patients referred for further evaluation of abnormal lab parameters. 
3. Patients referred  because of history of bleeding disorders 
 All the patients who gave their consent were enrolled into the study. There was no 
exclusion criteria for enrollment into the study. Post enrollment a detailed history was 
taken and the questionnaire administered by the registrars. A bleeding score was 
calculated based on the answers obtained after administration of questionnaire.  
Thereafter as our routine protocol the complete coagulation work-up was carried out. The 
baseline tests that we do in our laboratory include: 
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1. Complete Blood count(CBC) 
2. Bleeding Time(BT) in patients 3 years and older 
3. Platelet Function assay(PFA 200) 
4. Prothrombin Time(PT) 
5. Activated partial thromboplastin time(APTT) 
6. Thrombin Time(TT) 
7. Fibrinogen activity(Claus assay) 
8. Ristocetin cofactor assay(RicoF) 
9. Factor VIII levels 
For the purpose of doing the tests mentioned above the following samples were collected 
from the patients. The samples were collected using a vacutainer . 
1. 5 citrated tubes(5 ml) containing 3.2% Sodium citrate as anticoagulant. 
2. 4 citrated tubes(2.7ml) 
3. 1 Serum separator tube 
4. 1 EDTA tube containing 7.2 ml K2 EDTA as anticoagulant. 
After the samples were collected all of the above mentioned tests were done. The tests of 
our baseline tests helped guide further line of investigations. The reference methods used 
were Factor assays if after baseline investigations we suspected deficiency of coagulation 
factors. Light transmittance aggregometry was done if baseline investigations pointed 
towards Von willebrand disease or Platelet Function disorder which was further 
confirmed by Von Willebrand Antigen and Collagen or Factor VIII binding assay incase 
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of the former and Flow cytometry incase of the former. On every patient sample a global 
test of hemostasis namely TEG is also done.  
Thromboelastography or TEG is done on Haemoscope Thromboelastography analyzer  
using citrated whole blood,320 microlitre, 20 microitre recombiplastin and 0.2 M calcium 
chloride . The trace thus obtained was analyzed. 
All the patients whose baseline tests including TEG were normal were given the 
diagnosis of No intrinsic hemostatic defect and they served as the control of our study. 
Baseline parameters if abnormal were further investigated as mentioned above and the 
final diagnosis arrived at thereafter was noted. 
A bleeding score of 3 or more for pediatric patients, 6 or more for adult females and 4 or 
more for adult males was taken as significant or positive bleeding score. 
Any abnormality in any one of the parameters obtained from the trace of TEG was taken 
as positive TEG. 
 
PROCEDURE FOR TEG: 
Collection of specimen:  
1)Sample is collected within from the ante-cubital vein within 1 minute of application of 
tourniquet to avoid venous stasis.  
2) Proper needle must be used 19 to 21 G for adults, 22 to 23 G for children 
3) . Clear venipuncture. 
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4). Sample must be drawn in a plastic syringe.  If glass syringes cannot be avoided, they 
must be siliconized using silica spray or they must be smeared with Vaseline to prevent 
contact activation. 
5). The Coagulation tube should be filled without formation of foam.   Fast and sufficient 
mixing with anticoagulant (Citrate) solutions should be done by 5 to 6  inversions. 
 6). Correct labeling of the tube with hospital number. 
7). Add only the second syringe blood for Haemostatic workup. 
 8). Transport whole blood to laboratory as quickly as possible, as some coagulation 
factors are labile, and undue delay will affect coagulation testing. For practical purposes, 
blood should be tested within four hours of collection. In general, samples should be 
transported at room temperature (~22
o
C). Transport of whole blood at extreme 
temperatures (eg 4
o
C or >30
o
C) should be avoided as this may have an effect on test 
results. 
9) . Add 9 parts of blood to 1 part of buffered 3.2% trisodium citrate and mix well.  A 
suitable commercially supplied citrate anticoagulant tube will suffice (eg Becton 
Dickinson VACUTAINER systems [these are also often referred to as “blue top” tube], 
Greiner Vacuette, etc). Typically, 4.5ml of blood is added to 0.5ml-buffered trisodium 
citrate for normal coagulation studies.  For paediatric purposes use 1ml mini collect 
Greiner Vacuette. Note that underfilled tubes may not be acceptable for testing. 
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TEG: 
Procedure: 
Citrated Whole blood- 320 microlitre + 20 microlitre of Recombiplastin is added. 
(Recombiplastin-1/2000 is diluted in 20 microlitre of Imidazole buffer, so that the final 
concentration reaches 1/36000 in 340 microlitre of blood sample.) 
With this, 20 microlitre of 0.2 M calcium chloride is added to warmed cup. 
The sample is loaded on to the machine and the tracing obtained. 
STATISTICAL METHOD: 
The sample size was calculated  on the basis of retrospective values of TEG in 15 patients 
with Hemophilia A which is the bleeding disorder we commonly  encounter in our 
laboratory, so the sample based on 90% sensitivity and 90% specificity is 36 cases and 36 
controls with 95% confidence interval and 10% precision. Another objective of the study 
is to look at the difference between some parameters among cases and controls generated 
+by ROTEM. The parameters with the sample size for corresponding difference is 
tabulated below. 
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All the calculations were made for 80% power and 5% error. A sample size of 53 in each 
arm(total=106) is the highest for the difference in ly30. 
 
The data have been  summarized using mean(Standard Deviation) for continuous 
variables,frequency (percentage ) for categorical data. The Thromboelastgraphy 
parameters were compared among cases and controls using independent  t-test. Based on 
validated cut-off  values Thromboelastography parameters were classified and diagnostic 
accuracies were presented with 95% Confidence interval . All statistical analysis were 
done using STATA/IC 13.1 software. 
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RESULTS 
A total of 223 patients were enrolled into the study of which 97 were females and 126 
were males. Females comprised  43.5% of the patients and males comprised 56.5 % of 
the patients enrolled .  Of the 223 patients  201 patients that is 90.1 % of the patients were 
referred for increased bleeding tendency and a total of 18  patients comprising 8.07 % 
were referred for coagulation work-up as a result of incidentally detected abnormal 
coagulation parameters.  Only 4 patients were referred for evaluation of hemostasis 
because of abnormal family history. 
 
 The mean age of the patient was 18.31 years ranging from 0-67 years. There were 133 
patients in the pediatric age group(<18 years), and 90 patients who were older than 18 
years, .they comprised  59.6 and 40.3% of the enrolled patients respectively. The mean 
bleeding score was 6.91 ranging from 0 to 32. Ninety  patients amongst 223 patients had 
normal baseline investigations who were then labeled as patients with no intrinsic 
hemostatic defect, and served as the control in our study, this constituted 40% of our 
study population.  72 patients or  32.2% of the total patients enrolled were those of 
Clotting Factor deficiencies and among them 54% were those patients with Severe 
Hemophilia A.  Other patients in the group were 8 and 3 patients each of Mild and 
Moderate Hemophilia A respectively. There were 3 patients of Severe Hemophilia B and 
2 of Mild Hemophilia B.  There were 1 patient each of Severe Factor II and Factor XI 
deficiency. There were 2 patients each of  Factor VII and Factor X deficiencies and 3 
patients of Factor V deficiency. A total of 7 patients had Factor XIII deficiency which 
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accounted for a total of 10% of patients with clotting Factor deficiency. 2 patients had 
combined Factor deficiency. After coagulation factor deficiency the most common 
disorder encountered was Platelet Function Defects, 23 patients had Platelet Function 
disorder of which 18 were patients of Glanzmann Thrombasthenia, 2 patients with 
Bernard Soulier Syndrome and 3 patients with Platelet Function Disorder. 
11  patients with Von Willebrand Disease were enrolled into the study. Of the 11 patients 
6 patients had Von Willebrand Disease Type 3, 2 Patients had Von Willebrand Disease 
Type 2A/M and there were 1 patient each of Von Willebrand Disease Type 2b and Von 
willebrand Disease Type 1. There were 7 patients with Fibrinogen disorders. 3 patients 
each of Afibrinogenemia and Hypodysfibrinogenemia and 1 patient of 
Hypofibrinogenemia.(Table 4) 
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Table5: Frequency  of Diagnosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis Frequency 
1.No intrinsic hemostatic defect 90 
2. Clotting Factor Deficiency 72 
A. Severe Hemophilia A 
B. Moderate Hemophilia A 
C. Mild Hemophilia A 
D. Severe Hemophilia B 
E. Moderate Hemophilia B 
F. Severe Factor V deficiency 
G. Mild Factor X deficiency 
H. Factor XI deficiency 
I. Factor XIII deficiency 
J. Mild Factor VII deficiency 
K. Combined Factor deficiency 
39 
03 
08 
03 
02 
03 
02 
01 
07 
02 
02 
 
      3.Platelet Function Disorder 
 
23 
       A.  Glanzmann Thrombasthenia 
       B.  Bernard Soulier Syndrome 
       C.  Severe Platelet Function Disorder 
 
18 
02 
03 
      4. Von Willebrand Disease 11 
A. Von Willebrand Disease Type 1 
B. Von Willebrand Disease Type 2A/M 
C. Von Willebrand Disease Type 2B 
D. Von Willebrand Disease Type 3 
 
1 
2 
1 
6 
     5. Fibrinogen Disorders 07 
A. Afibrinogenemia 
B. Hypofibrinogenemia 
C. Hypodysfibrinogenemia 
 
03 
01 
03 
  6 .Acquired Bleeding 
Disorder+Improper history 
20 
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The average bleeding score for each condition is summarized in the Table No.7 below. 
Among 223 patients 75 had negative bleeding score and 143 had bleeding score that was 
higher than the bleeding score considered normal for that age group which was taken as 
positive.  
For the final analysis we excluded 20 people from our study, 2 on account of incomplete 
history and 18 as they were patients with acquired bleeding disorders and ISTH BAT is 
meant for inherited bleeding disorder. After 20 patients were excluded from the study the 
sensitivity and specificity of the ISTH BAT was  92.2%(85.8%-96.4%) and 65.5% 
(54.6%-75.4%)  respectively while the negative predictive value was  86.4%(75.7%-
93.6%).(Table 5(a),(b)). 
Table No. 5(a) and (b)  Shows the Sensitivity, Specificity,NPV,PPV,LR of Bleeding 
Score. 
Diagnosis 
Bleeding Score 
Positive 
Bleeding Score 
Negative 
Total 
Abnormal 107 09 116 
  Normal 30 57 87 
Total 137          66 203 
                                                 Bleeding Score (95
% 
 CI) 
Sensitivity 92.2% (85.8-96.4%) 
Specificity 65.5% (54.6%-75.4%) 
NPV 86.4%(75.7%-93.6%). 
PPV 78.1%(75.7%-93.6%) 
LR 2.6 (1.99 - 3.59) 
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We wanted to calculate  the specificity and sensitivity of ISTH BAT in mild to moderate 
bleeding or rare bleeding disorder so we analyzed the result after excluding the cases of 
Severe Hemophilia A and B , after excluding these cases the sensitivity and specificity of 
ISTH BAT was found to be 89.1%(81.2%-96.1%) and 63.3%(52.5- 73.2%)with a 
negative  predictive value of 87.6%(78.8%-95.5%).(Table 6(a),(b)) 
 
Table No. 6(a) and (b)  Shows the Sensitivity, Specificity,NPV,PPV,LR of  Bleeding 
Score after Severe Hemophila patients are excluded. 
Diagnosis BS Positive BS Negative Total 
Abnormal 66 08 74 
Normal 33 57 90 
Total 99 65 164 
 
Table 6(b) 
                  Bleeding Score after Severe Hemophilia A and B is excluded 
Sensitivity 89.1%(81.2%-96.1%) 
Specificity 63.3%(52.5- 73.2%) 
NPV 87.6%(78.8%-95.5%). 
PPV 66.7% ( 56.5%-75.8%) 
LR 2.47 ( 1.86 -3.27) 
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Table 7:The average bleeding score for each diagnosis. 
Diagnosis 
 Average Bleeding 
score 
Range No. of patients 
No intrinsic hemostatic 
defect 
3.06 0-11 90 
Severe Hemophilia A 13.18 0-31 39 
Mod. Hemophilia A  8.67 4-12 03 
Mild Hemophilia A 5.63 0-14 08 
Severe Hemophilia B 11.67 7-18 03 
Moderate Hemophilia B 6.50 3-10 02 
Factor X deficiency 10.50 4-17 02 
Factor VII 
Deficiency 
9.50 9-10 02 
Combined Factor 
deficiency 
5 3-7 02 
Factor V deficiency 12.33 4-26 03 
Factor XIII deficiency 10.15 5-16 07 
Glanzmann 
Thrombasthenia 
10.44 2-32 18 
Bernard Soulier 
Syndrome 
18.50 18-19 02 
Platelet Function  
Defect 
2 0-4 02 
Von Willlebrand Disease 
Type 2A/M 
06 2-10 03 
Von Willebrand Disease 
Type 3 
9.17 4-20 06 
Afibrinogenemia 7 4-9 03 
Hypodysfibrinogenemia 12 4-20 03 
Acquired bleeding 
disorders 
3.72 2-8 18 
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Since there were only one patient each for Factor XI deficiency. Prothrombin deficiency 
,Von Willebrand DiseaseType 1 and  Type 2B and Hypofibrinogenemia the mean 
bleeding score in these conditions were not calculated. 
Thromboelastography: 
Of the 205  patients analyzed  104 patients had abnormal TEG who were eventually 
found to have a bleeding disorder. In another 16 patients who were diagnosed to have a 
bleeding disorder TEG was normal. 
In 71  patients who were found to have no bleeding disorder TEG was also normal. TEG 
in 13  patients was abnormal who were not diagnosed to have any bleeding disorder. 
Considering all these values  Sensitivity of TEG in diagnosing bleeding disorder was 
found to be 86.0%(78.5%-91.6%), whereas specificity was found to be  85.7%(76.4-
92.4%). The positive predictive value  and the negative predictive value were  
89.7%(82.6%-94.5%) and 80.9%(71.2%-88.5%) respectively.(Table 8(a), 8(b)) 
Table No. 8(a) and (b)  Shows the Sensitivity, Specificity,NPV,PPV,LR of TEG  after 
Severe Hemophila patients are excluded. 
TEG Diagnosis 
Abnormal 
Diagnosis 
Normal 
Total 
Positive 104 12 116 
Negative 17 72 89 
Total 121 84 205 
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Table no. 8(b) 
                     TEG PARAMETERS IN  BLEEDING DISORDER 
Sensitivity 86.0%(78.5%-91.6%) 
Specificity 85.7%(76.4-92.4%). 
NPV 80.9%(71.2%-88.5%) 
PPV 89.7%(82.6%-94.5%) 
LR  6.02 (3.55-10.2) 
  
The K time in TEG represents clot kinetics, we looked for its sensitivity and specificity 
and found that sensitivity was 57.9%,specificity was 89.9%. 
We also calculated the sensitivity and specificity of  TEG after the diagnosis was grouped 
into following groups. 
1)Clotting Factor deficiencies(except Fibrinogen and FXIII) 
2)Platelet Function disorders  
3)Fibrinogen Disorders 
For Clotting Factor deficiencies excluding Fibrinogen and Factor XIII deficiency  but 
Von Willebrand Disease  included , we looked for the ability of  R time and angle to 
predict the presence of Bleeding disorders. Of the 66 patients in the group  
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R time: 
Of the total 66 patients in this group R time was prolonged in 55 and normal in 9. Among 
normal controls 11 had prolonged R time and 78 were normal, giving an over- all 
sensitivity of 86.4%(75.7%-93.6%) and specificity of  87.6%(79%-93.7%). The 
positive and Negative Predictive value were respectively 83.8%(72.9%-91.6%)and 
89.7%.( 81.3%-95.2%)(Table 9(a),Table 9(b)) 
Table No. 9(a) and 9(b)  Shows the Sensitivity, Specificity,NPV,PPV,LR of TEG  (R 
time  ) in coagulation factor deficiencies. 
Diagnosis R  Positive  R Negative Total 
Abnormal  57 09 66 
Normal 11 78 89 
Total 68 87 155 
 
Table 9 (b) 
 R time  in Coagulation Factor deficiencies(Fibrinogen and FXIII deficiencies excluded) 
Sensitivity 86.4%(75.7%-93.6%) 
Specificity 87.6%(79%-93.7%). 
NPV 89.7%.( 81.3%-95.2%) 
PPV 83.8%(72.9%-91.6%) 
LR  6.02 (3.55-10.2) 
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The angle in TEG is mainly contributed by fibrinogen and some extent by platelets. 
Clotting factors also contribute to the angle. We wanted to analyse the angle in the above 
mentioned group. Of the 66 patients analyzed 46(69.6%) patients had decreased angle.  
When R time and angle were taken together the sensitivity and specificity was found to 
be 87.9% and 78.7% respectively and the positive predictive value was 75.3% and 
negative predictive value 89.3%.(Table 10(a),10(b)) 
 
Table No. 10(a) and 10(b)  Shows the Sensitivity, Specificity,NPV,PPV,LR of TEG  (R 
time and angle  ) in coagulation factor deficiencies. 
Diagnosis R and Angle Positive Negative Total 
Abnormal 58 8 66 
Normal 19 70 89 
Total 77 78 155 
 
Table:10(b) 
  R time  and angle  in Coagulation Factor deficiencies(Fibrinogen and FXIII deficiencies 
excluded) 
Sensitivity 87.9 87.9  %  (77.5%-94.6%) 
Specificity 78.7%(68.7%-86.6%) 
NPV 89.7%(80.8%-95.5%) 
PPV 75.3%(64.2%-84.4%) 
LR  4.12 (2.74-6.19) 
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Platelet Function Defects : 
We also analyzed the ability of MA and angle in platelet function disorder  and found that 
of the total 24 patients of Platelet Function disorder MA was decreased in  23 giving it a 
sensitivity of  95.8%.(Table 11(a) and (b)) 
Table No. 11(a) and 11(b)  Shows the Sensitivity, Specificity,NPV,PPV,LR of TEG  
(MA ) in coagulation factor deficiencies. 
Table 11(a) 
Diagnosis MA Positive Negative Total 
Abnormal 23 1 24 
Normal 53 36 89 
Total 76 37 113 
 
Table 11(b) 
                        MA in Platelet Function Disorders 
Sensitivity 87.9 
87.8 95.8 %(78.9%-99.9%) 
Specificity 40.4%(30.2%-51.4%) 
NPV 97.3%(85.8%-99.9%) 
PPV 30.3%(20.2%-41.9%) 
LR  1.61(1.33-1.91) 
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While the most major contribution to angle is done by Fibrinogen, 25% of it is 
contributed by Platelets. We found that of 24 patients , 19 had low angle,. Angle in 
platelet function disorders have a sensitivity, specificity, PPV and NPV of 
79.2%,83.1%,72.8%,97.9% respectively. Table 12(a) 
Table No. 12(a)  Shows the Sensitivity, Specificity,of TEG  (ALPHA  ) in coagulation 
factor deficiencies. 
Table 12(a) 
Diagnosis Angle Positive Angle Negative Total 
Abnormal 19 5 24 
Normal 15 74 89 
Total 34 79 113 
When  MA and angle were taken together the findings were as follows. 
 
Table No. 12(b,c)  Shows the Sensitivity, Specificity, NPV,PPV,LR of TEG  (ALPHA 
+MA  ) in coagulation factor deficiencies. 
Diagnosis MA + angle Positive Negative Total 
Abnormal 23 1 24 
Normal 54 35 88 
Total 77 36 113 
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Table no. 12 (c) 
                              MA  and Angle in Platelet Function Disorders 
Sensitivity 87.9 
8799 95.8%(78.9%-99.9%) 
Specificity 39.3%(29.1%- 50.3%) 
NPV 97.2%(85.5%-99.9%) 
PPV 29.9%(20.0%-41.4%) 
LR  1.58(1.31-1.9) 
When MA and angle were combined the sensitivity was 95.8%. (Table 12 (b,c)) 
There were only 4 patients with Fibrinogen defects, all 4 of them had reduced angle and 
MA. 
For FXIII deficiency out of 7 patients only 2 patients had mildly prolonged TEG, 1 had 
significant  lysis rest were normal. 
The third objective of our study was to calculate the sensitivity and specificity of 
Thromboelastography and Bleeding Score taken together as a screening tool for Inherited 
bleeding disorders. When that was done the sensitivity,specificity,NPV and PPV were 
97.5%,56.5%,94% and 76.3% respectively. 
 
 
 
56 
 
Table No. 13(a) and 13(b)  Shows the Sensitivity, Specificity,NPV,PPV,LR of TEG and 
BS  in coagulation factor deficiencies. 
Diagnosis BS +TEG Positive Negative Total 
Abnormal 116 3 119 
Normal 36 47 83 
Total 152 50 202 
 
Table 13 (b) 
                              Bleeding Score and TEG Parameters 
Sensitivity 8799 97.5%(92.8%-99.5%) 
Specificity 56.6%(45.3%-67.5 %) 
NPV 94%(83.5%-98.7%) 
PPV 76.3%(68.7%-82.8%) 
LR  2.25(1.75-2.88) 
 While there was not much difference between cases and controls in terms of age, there 
was  difference in bleeding scores, R time, K time, angle and Maximum amplitude which 
was significant between cases and control.  p value being less <0.0001 in case of all the 
parameters mentioned. 
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Table 14: Comparison of age, TEG parameters between Cases and Control 
PARAMETER            CASES(MEAN)        CONTROL(MEAN)             p  Value                                                                                                  
Age                              18.41                            18.68                                   0.9 
R Time                         19.49                             7.49                                    <0.0001 
K Time                         7.09                              2.89                                     <0.0001 
Angle                            41.66                          61.50                                    <0.0001 
MA                               57.06                           67.21                                     <0.0001 
Ly30                            0.24                               1.39                                        0.1 
                              
 
Table 14(b): Compilation of Diagnostic Accuracy of different methods: 
METHOD(S)           SENSITIVITY             SPECIFICITY                 NPV               PPV  
    1.BAT                    92.2%                           65.5%                         86.4%             78.1% 
2.  TEG                     86.0%                            85.7%                        80.9%              89.7% 
3. BAT +TEG          97.5%                            56.6%                         94%                76.3%                                       
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Figure 4 :TEG tracing shows  increased K time, decreased angle, decreased MA and 
increased lysis in Hypodysfibrinogenemia. 
 
 
 Figure 5:TEG tracing shows increasesd R time, K time , reduced angle in patient with 
Severe Hemophilia B. 
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Figure 6: TEG tracing in a patient with Severe Hemophilia A,Prolonged R time, K time 
and reduced angle can be appreciated. 
 
 
Figure 7 : TEG tracing in a patient with Severe Hemophilia B ,Prolonged R time, K time 
and reduced angle can be appreciated. 
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Figure8 : TEG tracing in a patient with Afibrinogenemia shows extremely prolonged R 
time with no clot formation. 
 
 
Figure 9: TEG tracing in a patient with Factor XI deficiency shows a normal trace. The 
patient had no bleeding symptom and was referred for investigation of prolonged APTT. 
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Figure 10: TEG tracing in a patient with Bernard Soulier Syndrome, Prolonged K time 
and reduced angle can be appreciated. 
 
 
Figure 11: TEG tracing in a patient with Glanzmann Thrombasthenia shows increased K 
time,  increased  angle  and severely reduced MA. 
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Figure 12: TEG tracing in a patient of Factor XIII deficiency shows decreased angle  and 
increased lysis.  
 
 
Figure 13: TEG tracing in a patient of Severe Factor V deficiency prolonged R time, K 
time and reduced angle. 
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Figure 14: TEG tracing in FXII deficiency shows, prolonged R time, prolonged K time 
and decreased angle. 
 
 
Figure 15: TEG tracing in Von Willebrand Disease type 3, does not show any marked 
abnormality save for mildly prolonged R time. 
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Discussion 
 
As is known the ususal screening tools like BT, PT, APTT and  have a very low 
sensitivity , specificity and predictive values in diagnosis of bleeding disorders.(53,54) 
The usefulness of bleeding history in identification of bleeding disorders have been 
evaluated prospectively by only a few studies.(11) 
In this study that was carried over a period of 6 months in between December 2015 – 
May 2016, 223 patients were studied. These patients are referred to our Laboratory to 
rule out abnormalities of hemostasis.  We divided patients into 3 main groups, they were 
patients referred for increased bleeding tendency, for incidental finding of deranged lab 
parameters and those referred for evaluation because of positive Family history. We 
found that out of  223 patients 201 patients that is 90.1 % of the patients were referred for 
increased bleeding tendency and a total of 18  patients comprising 8.07 % were referred 
for coagulation work-up as a result of incidentally detected abnormal coagulation 
parameters.  Only 4 patients were referred for evaluation of hemostasis because of 
abnormal family history. In a similar study done by Tosetto et al out of Two hundred and 
fifteen  patients studied , 71 were  referred for evaluation incidental finding of abnormal  
test results, 105 for the presence of  some bleeding symptoms, and 39 for positive family 
history (34) .  
Out of the 223 patients , 90 patients, on investigation were found to have no abnormality 
of hemostasis that is almost 40 % of the patients referred.  In Clinical practice the utility 
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of BAT may be either to exclude bleeding disorder in an unselected group or to identify 
patients who are likely to have a bleeding disorder. In the former case BAT should have a 
high sensitivity and NPV, hence the need for extensive investigation that usually entails 
investigation af a bleeding disorder is negated. 
On the other hand , if the BAT is intended for the latter, it would need a good specificity 
and a good PPV.(34) 
While the ISTH BAT have been evaluated prospectively for specific bleeding disorders 
as of now, there is no study where the ISTH  BAT has been evaluated for use in all 
bleeding disorders. The use of BAT has been mainly limited to the diagnosis of Von 
Willebrand Disease and also in Platelet Function disorder.Tosetto et al evaluated the 
clinical utility of BAT in mild bleeding disorders, however the BAT used in this 
particular study was MCMDM BAT (34–36). 
In our study we evaluated the utility of ISTH BAT in all patients referred for evaluation 
of hemostasis, prospectively.We enrolled 223 patients referred to our laboratory for 
evaluation of hemostasis. 
Among 223 patients 75 had negative bleeding score and 143 had bleeding score that was 
higher than the bleeding score considered normal for that age group which was taken as 
positive.   20 patients were excluded from the study . 
The sensitivity and specificity of the ISTH BAT was  92.2% and 65.5% respectively 
while the negative predictive value was  86.4%. 
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Out of the 203 patients who were finally analyzed for the bleeding score versus the 
diagnosis, 9 patients were patients with negative bleeding score who were diagnosed to 
have a bleeding disorder. These included 1 patient with Factor XI deficiency, 1 patient of 
Severe Hemophilia A, 1 patient of Glanzmann Thrombasthenia, 1  patient of platelet 
function defect, 3 of Mild Hemophilia A and one patient each of Von Willebrand Disease 
Type 2B/Platelet Type Von willebrand Disease and 1 of Von Willebrand Disease Type 
2A/M. 
TABLE 15 : COMPARISON OF STUDIES EVALUATING UTILITY OF ISTH 
BAT. 
STUDY BAT NPV PPV 
A Tosetto et al,2011 
MCMDM-1 VWD 
For Mild Bleeding Disorders 
99.2% 77.5% 
Lowe et al,2014 
ISTH BAT, for  ability to detect 
Platelet Function defect on 
Lumiaggregometry 
50% 54% 
M Bowman et 
al,2008 
MCMDM-1 VWD 1 0.20 
M Bowman et al 
,2009 
Pediatric Bleeding Questionnaire 0.14 0.99 
CMC Vellore 
2015-2016 
ISTH- BAT 86.4% 77.1% 
Rashid et al 2016 
ISTH-BAT for Platelet Function 
Disorder 
89.5% 49% 
Kaur et al 2016 
ISTH BAT for Platelet Function 
Disorder 
0.9 1 
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We attributed  the increased sensitivity  of BAT in our study  to large number of Severe 
Hemophilia A and B, as these patients have excessive bleeding and the score in them is 
likely to be higher, so we calculated  the specificity and sensitivity of ISTH BAT in mild 
to moderate bleeding and rare bleeding disorders after excluding the cases of Severe 
Hemophilia A and B ,sensitivity and specificity of ISTH BAT was found to be 90.4% and 
63.3% with a negative predictive value of 89.1% and Positive Predictive value of 66.7%.  
The advantage of  BAT in all the past and the present study appears to be the high 
negative predictive value, a negative BAT essentially rules out a bleeding disorder. The 
current study has findings comparable to most of the previous study in terms of Negative 
predictive value. To our knowledge apart from the ones already mentioned there are no 
prospective studies that have used ISTH BAT for evaluation of bleeding disorders. The 
attempts to validate ISTH-BAT are ongoing. 
In our study 30 patients had positive BS, and  were finally diagnosed to have no bleeding 
disorder.In  the pediatric population there are many patients with pubertal menorrhagia 
who are treated with hormones and anti-fibrinolytics, the cut-off for pediatric population 
being low i.e  3, many of the bleeding scores were falsely positive in this group,infact 
24/30 cases i.e 80% of the false positive cases were in the pediatric age group,keeping a 
single cut off in the age-group of 0-18 may help in increasing the sensitivity at the cost of 
specificity ,as in this age group , with a wide-range , girls attain menarche and also by 
adolescent age many of the patients would have encountered significant hemostatic 
challenges so an intermediate category or an adolescent category with a higher cut off if 
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considered, may help improve the specificity of the tool  . Significant false 
positivity(20% of False Positive cases) were also contributed by females with 
menorrhagia. In our opinion patients with menorrhagia could  be administered the PBAC 
questionnaire in conjunction with ISTH BAT, this would heighten the specificity of 
bleeding assessment tool. The low specificity and high false positivity may also be 
attributed partly to indiscriminate use of anti-fibrinolytics and transfusion in our set-up. 
Among the 223 patients enrolled in our study , 90 patients i.e 40 % were found to have no 
bleeding disorder, in our set-up BAT should have a high sensitivity and NPV, hence the 
need for extensive investigation that usually entails investigation af a bleeding disorder is 
negated.  With the sensitivity and specificity of the ISTH BAT at  92.2% and 65.5% 
respectively and negative predictive value of  86.4%, ISTH BAT can be used as a good 
screening tool, our current practice of using this in conjunction with other screening test 
is good. 
 
While the  initial utility of TEG was meant to reduce transfusion requirement in 
complicated surgeries but now its utility has expanded to bleeding and thrombotic 
disorder.(39) TEG and its utility in bleeding disorder has also been   studied. 
Zia et al studied TEG in the diagnosis of  RBDs. This was a retrospective study done on 
26 patients with rare bleeding disorder.  They had 4  patients of Fibrinogen deficiency, 1 
patient of pro-thrombin deficiency, 1 Factor V deficiency, 
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3 patients of combined Factor V and Factor VIII deficiencies, 1 of Factor XI and 4 of 
Factor XIII deficiency. Other disorders included in the study were 1patient of PAI 1 
deficiency, 1 of Vitamin K dependent clotting factor deficiency, 14 cases of Glanzmann 
Thrombasthenia  and 1 patient of Bernard Soulier Syndrome. Apart from this there were 
2 patients, 1 each of High Molecular Kininogen deficiency and 1 of FXII deficiency. (13) 
In this apart from the usual parameters of TEG they also studied the dynamic property of 
clot formation by transforming the TEG data into a velocity curve or the V curve. The 
parameters assessed under V curve were mean rate of thrombus generation (MRTG.(13) 
This study concluded that when they used all the parameters above they found that 25/26 
patients had abnormal TEG giving it a sensitivity of 100%. 
In a study done by Chitlur_et al , where they studied 58 children with severe Hemophilia 
and their TEG profiling was done found that  the R time in children with Severe 
Hemophilia without inhibitors was significantly prolonged than the normal controls 
(p<0.001) and when they compared the time taken for clot formation in Severe 
Hemophilia A with inhibitors as against those without inhibitors, the R time was 
significantly prolonged in the former catergory.(p<0.001)The discrepancy often observed 
between phenotype and genotype in patients of severe Hemophilia A  have been studied 
and it was seen that patients who had less bleeding had better thrombin generation 
capacity(46). The utility of TEG in titration of recombinant FVII has also been 
evaluated.(44) 
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Zia et al in their retrospective study found TEG to be of limited utility as a screening test 
for Inherited coagulation disorder. In their retrospective study they found that on 195 
patients with 29 cases of diagnosed bleeding disorders that comprised of  16 Von 
Willebrand  DiseaseType 1, 
6 patients with Factor VII deficiency, 3 patients of Factor XII deficiency, 2 patients of 
Factor XI deficiency and One patient of delta storage pool disorder they found TEG to 
have very poor sensitivity and specificity.(50) 
In our study  Of the 205  patients analyzed  104 patients had abnormal TEG who were 
eventually diagnosed to have a bleeding disorder. In another 16 patients who were 
diagnosed to have a bleeding disorder TEG was normal. 
In 71  patients who were found to have no bleeding disorder TEG was also normal. TEG 
in 13  patients was abnormal who were not diagnosed to have any bleeding disorder.  
Sensitivity of TEG in diagnosing bleeding disorder was found to be 86.7%, whereas 
specificity was found to be  84.5%. The positive predictive value  and the negative 
predictive value were  88.9% and 81.6% respectively 
Of the 16 patients in whom the TEG was normal and were diagnosed to have bleeding 
disorder, the distribution were as follows: 
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Table 16: Patients with False Negative TEG 
Diagnosis No.of patients 
Factor XI deficiency 1 
Mild Hemophilia A 3 
Severe Hemophilia A 1 
Bernard Soulier Syndrome 1 
Von Willebrand Diisease Type 2A/2M 3 
Von Willebrand Disease Type 3 1 
Factor XIII deficiency 2 
Mild and Severe Factor VII deficiency 2 
Mild Platelet Function defect 1 
Combined Factor deficiency 1 
 
Among the false negative TEG  all the patients of Mild Hemophilia A had Factor levels 
above 30%. Same was the case with mild deficiency of Factor VII. One case of Severe 
Factor VII deficiency and one Severe Hemophilia A with normal TEG were patients who 
received Factor infusions few days prior to the test  and the TEG was performed without 
adequate wash-out period. If these two cases were to be excluded from the study the 
overall sensitivity  would go upto 86.5%. 
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The TEG parameters we analyzed for this study were R time,K time, Alpha angle, 
Maximum Amplitude and Lysis. Like the study described earlier by Zia et al where they 
have derived a different parameter like the V curve , it would probably be worthwhile to 
look at other parameters for their sensitivity and specificity in a similar setting. 
Parameters worth looking at would be the G and Coagulation Index or CI and a further 
study to analyse these parameters would be interesting. 
To our knowledge there have been only two studies both by Zia et al that have evaluated 
the sensitivity and specificity of TEG as a screening tool for bleeding disorders. 
In 2011 Zia et al in their retrospective analysis of 195 patients found that the sensitivity 
of the R time to diagnose a clotting factor (including low factor VIII with vWD) 
deficiency was only 58% with a specificity of 78%. R time correlated with PTT and PT 
in up to 50% (vWD: 12%, FVII deficiency: 33%, FXII: 33%, FXI: 50%) of the patients. 
R time was also prolonged in 46/166 (28%) patients without a definitive bleeding 
disorder.  In this study the TEG performed with low dose tissue factor (1:190 000 
concentration).(50) 
The same authors in 2015 using 1:10 000 dilution of  recombinant human tissue factor in 
a retrospective analysis of  26 patients obtained a sensitivity of 100%in screening of 
bleeding disorder. 
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 We also analysed  few individual parameters of TEG for specific disorders,the R time 
and angle in clotting Factor deficiencies excluding the Factor XIII and  Fibrinogen 
disorder patients but we included the patients with Von Willebrand Disease, of the total 
66 patients in this group R time was prolonged in 55 and normal in 9. Among normal 
controls 11 had prolonged R time and 78 were normal, giving an over- all sensitivity of 
86.4% and specificity of  87.6%. The positive and Negative Predictive value were 
respectively 83.8 and 89.7%.  This is higher than the sensitivity and specificity obtained 
by Zia et al with  sensitivity of the R time to diagnose a clotting factor (including low 
factor VIII with vWD) deficiency was only 58% with a specificity of 78%. The 
difference probably can be attributed to the difference in concentration  of tissue factors 
being used. In  our lab use 1 in 2000 dilution. Whether Tissue factor concentration 
influences the over all  sensitivity of TEG needs  to be validated by further study. 
When R time and angle were taken together the sensitivity and specificity was found to 
be 87.9% and 78.7% respectively and the positive predictive value was 75.3% and 
negative predictive value 89.3% in clotting Factor deficiencies. 
We also analyzed the ability of MA and angle in platelet function disorder  and found that 
of the total 24 patients of Platelet Function disorder MA was decreased in  23 giving it a 
sensitivity of  95.8%. 
When MA and angle were combined the sensitivity was 95.8%.  
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There were only 4 patients with Fibrinogen defects, all 4 of them had reduced angle and 
MA. 
In Factor XIII deficiency out of seven patients TEG was abnormal for two parameters in 
three patients, one patient had higher lysis than normal and two had prolonged R time but 
due to lesser number of these patients we cannot categorically say if TEG is a good 
screening tool  in these disorders or not. Probably a study with higher number of FXIII 
deficient patient will be required for a definite conclusion. 
The final objective of our study was to look for the specificity  and sensitivity of 
Bleeding Score and TEG  together as a screening tool for inherited bleeding disorders, 
When that was done the sensitivity,specificity,NPV and PPV were 97.5%,56.5%,94% 
and 76.3% respectively. In this group there were 3 false negative patients 1 patient  a 10 
year old female patient  with Von Willebrand Disease 2A/M , lack of bleeding symptoms 
in her  can be attributed to variable penetrance of VWD  and also FVIII levels of over 
190%, The other patient was a patient with Mild Hemophilia A with FVIII levels of over 
30% and a 60 year old gentleman with FXI deficiency with FVIII levels over 200%. It is 
understandable that such high levels of FVIII would prevent bleeding thereby having low 
bleeding score and also would result in normal TEG . To the best of our knowledge there 
is no study where ISTH  BAT and TEG have been used together as a screening tool for 
bleeding disorders. 
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The use of these two modalities together as a screening tool gave us a sensitivity and 
NPV of 97.5% and 94% respectively, and the use of these two together for the same may 
be considered. We also compared the TEG parameters , BS and age of the patients in 
between cases and control and we found that there is a significant difference in between 
the patient and the controls in both BS and TEG parameters. P < 0.001. 
 The major utility of BAT is in distinguishing bleeders from non-bleeders our study had 
many patients with Severe Hemophilia A and few of B, barring a few most of the 
Hemophilia patients have excessive bleeding.(55), so a BAT as a screening tool , as 
sensitive as it may be,  can be redundant and the presence of large number of these 
patients also could have led to heightened sensitivity in  our study. However  BAT score 
being a very efficient tool to document bleeding score may be included in a composite 
score for Hemophilia in the lines of one devised by Schulman et al.(32) The utility of 
BAT Score in this setting would be worth evaluating. The long administration time of (20 
minutes)BAT also is a reason why its acceptability may be lower in busy clinical practice 
, so an attempt toward patient administered BAT score should be taken. In a multi-
lingual,multi-ethnic population like ours this will be a challenge but an attempt in that 
direction would be a worthwhile endeavour now that the importance of well taken history 
has been proven. Also a questionnaire in a patient’s mother tongue would probably be 
able to acquire more valid and true information. (56) 
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This study also has many limitations. Many of these are the inherent limitations of  a 
BAT score. The bleeding score obtained post administration of  a BAT depends on  
history given by the patient , so an improper history will lead to a false bleeding score. To 
overcome this we used the Thromboelastography in conjunction with BAT. 
As we enrolled consecutive patients referred to our lab , we had many patients with 
Severe Hemophilia and there were few cases of other rarebleeding disorders. Probably a 
study done over a longer duration with significant numbers in each category of Bleeding 
disorders can be undertaken for adequate representation of mild, moderate and rare 
bleeding disorders. Also there is no gold standard reference test for all bleeding disorders 
so the tests that were done to arrive at a final diagnosis were the ones that is a part of our 
laboratory protocol. 
We also run  the Thromboelastography only in the EXTEM mode and we evaluated only 
R time, K time, Angle, MA and Ly 30 , it remains to be seen if running the TEG in other 
modes and including other parameters or derivation of other parameters would increase 
the sensitivity and specificity of the study.  
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SUMMARY AND CONCLUSION 
 Patients referred to our laboratory for evaluation of hemostasis in between 
November 2015 to May 2016  were enrolled into the study after taking informed 
consent. 
 ISTH BAT questionnaire were administered to each patients who consented to be 
a part of the study. 
 Per Protocol all the tests were done including Thromboelastography and the 
positivity and negativity of both these modalities were analysed with the final 
diagnosis. 
 Sensitivity and Specificity of Bleeding score , Thromboelastography separately 
and  both  taken together in being able to identify Bleeding disorders were  
studied. 
 The TEG parameters and Bleeding scores were compared among cases and 
controls using independent t-test. 
 Based on validated cut-off points for both TEG and BS, diagnostic accuracies 
were presented with 95%  confidence interval. 
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 The sensitivity and specificity of the ISTH BAT was  92.2%(85.8%-96.4%) and 
65.5% (54.6%-75.4%)  respectively while the negative predictive value was  
86.4%(75.7%-93.6%). 
 Sensitivity of TEG in diagnosing bleeding disorder was found to be 86.0%(78.5%-
91.6%), whereas specificity was found to be  85.7%(76.4-92.4%). The positive 
predictive value  and the negative predictive value were  89.7%(82.6%-94.5%) 
and 80.9%(71.2%-88.5%) respectively. 
  The sensitivity and specificity of Thromboelastography and Bleeding Score taken 
together as a screening tool for Inherited bleeding disorders 
sensitivity,specificity,NPV and PPV were 97.5%(92.8%-99.5%),56.5%(45.3-
67.5%),94%(83.5%-98.7%)  and 76.3%(68.7%- 82.8%) respectively. 
 There was significant difference in between the cases and controls in terms of  R 
time, K time, angle and MA and BS. 
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Conclusion 
 BAT can be used as ascreening tool  to distinguish bleeders from none bleeders, 
given the high sensitivity and  NPV , a normal bleeding score would rule out a 
bleeding disorders. 
 TEG can be an effective screening tool in  Inherited bleeding disorders however 
other parameters of TEG needs further evaluation. 
 TEG and BS taken together can be an extremely effective screening tool for 
inherited bleeding disorders. 
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 DATA COLLECTION SHEET. 
NAME: 
AGE: 
SEX: 
HOSPITAL NUMBER:_____________ 
REFERRED FOR:_______________________________________ 
BLEEDING SCORE: ________________________ 
Plt count________________________ 
BT___________________,        
PT________ INR________ 
APTT__________ 
TT_______________ 
TEG : 
R TIME__________,  
K________________, ALPHA________________, 
MA_____________________,LY 30______________. 
Reference Method________________ 
DIAGNOSIS__________________________ 
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bleedscore pltcount bt pt inr aptt tt rtime k alpha ma ly30 reference diagnosis
0 120000 2.2 10.7 1 61.3 12.3 7.4 1.7 66.6 66.1 0 Factor assay Factor XI deficiency
17 165000 2.3 10.9 1 151.8 11.7 22.8 7 23.6 59 0 Factor Assay Severe Hemophilia A
4 158000 3 11.7 1.1 39.5 13.4 6.3 2 60.6 66.4 0 No intrinsic hemostatic defect
6 353000 10.9 1 89.3 13.5 9.9 2.5 56.4 59.1 0 Von willebrand Factor antigen Von Willebrand Type 3
7 346000 2.3 12.3 1.1 159.6 12.6 38.2 7.3 30.3 64.5 0 Factor Assay Severe Hemophilia B
4 312000 3 34.9 3.2 42.2 47.2 11.1 11.8 4.8 29.6 Fibrinogen activity and antigen Hypofibrinogenemis with FXII  deficiency
7 390000 2.3 11.4 1 156.9 13.2 40.5 9.3 22.7 50.5 0 Fsctor Assay Severe Hemophilia A
6 178000 15 11.4 1.1 43.9 13.4 14.5 17.9 11.3 0 LTA/Flow Cytoometry Glanzmanns Thrombesthenia
4 393000 3.3 12.1 1.1 30.5 12.8 8.3 1.9 63.7 66.5 0 No intrinsic hemostatic defect
2 280000 2.3 11 1 37.5 13 4.7 1.2 55.6 71 0 No intrinsic hemostatic defect
4 327000 29.5 2.7 78.7 13.2 14.3 2.2 62.1 61.4 1 Factor assay Mild Factor X Deficiency
7 373000 2.3 61.6 3.4 180 14.3 21 3.6 4 57.6 0 Factor assay Severe Factor V deficiency
2 21000 2 11.9 1.1 36.9 13.5 5.9 2 61.3 66.2 1.2 No intrinsic hemostatic defect
2 123000 3 11 1 38.3 14 4.7 1.8 66.1 70 0 No intrinsic hemostatic defect
0 100000 2.3 12.4 1 35.7 13.7 6.9 2.2 59.8 67.3 0 No intrinsic hemostatic defect
0 454000 3.3 12.2 1.1 44.2 14 9.2 2 65.3 76.9 0 No intrinsic hemostatic defect
8 519000 120 10 180 120 Fibrinogen assay and activity Afibrinogenemia
1 163000 2 10.1 0.9 29.7 13.9 4.5 1.3 71.9 71.7 0 No intrinsic hemostatic defect
5 228000 3.3 10.1 0.9 34.6 13.6 6.2 1.7 66.4 65.3 0.3 No intrinsic hemostatic defect
12 29000 120 10 180 81.3 9.9 15.3 14.3 0 Fibrinogen assay and activity Hypodysfibrinogenemia
6 314000 2.3 10.2 0.9 53 13.4 9.7 3 52.1 60.3 0 Von willebrand Factor Antigen assay Von Willebrand Disease Type 1
0 229000 2.3 10.8 1 55 12.3 5.8 1.3 71.7 70.4 0.3 No intrinsic hemostatic defect
10 173000 2 10.6 1 77.7 15.4 24.2 6.2 33.8 51 0 Factor Assay Moderate Hemophilia B
0 150000 3.3 10.5 0.9 52.3 13.2 8.4 1.7 62.7 66.8 0 Factor Assay Mild Hemophilia A
6 120000 2.3 10.4 0.9 52.6 12.4 8.4 1.3 72.7 73.1 0 Factor Assay Mild Hemophilia A
16 164000 3.3 10.3 0.9 38.4 13.4 7.3 3.1 51.9 53.2 0.4 Factor assay Factor XIII deficiency
7 351000 2.3 10.7 1 38.5 14 7.6 1.9 65.5 70.4 0 No intrinsic hemostatic defect
6 141000 5.3 10.6 1 33.5 14.1 7.4 1.8 47.1 68.3 0 LTA Storage pool defect
22 375000 2 10.7 1 165.2 14.9 94.2 4.9 49.7 26.7 0 Factor Assay Severe Hemophilia A
2 330000 3 10.6 0.9 37.1 13.1 5.8 1.5 69.5 73.9 0 No intrinsic hemostatic defect
8 203000 15 10.3 0.9 25 13.7 5.9 46.2 15.4 0 LTA/Flow cytometry Glanzmanns Thromosthenia
7 246000 11.5 1.1 27.4 13.4 8.1 46.2 15.1 0 LTA/Flow Cytometry Glanzmanns Thrombosthenia
0 381000 3 10.3 1 180 13.9 23.3 3.2 55 60.7 1 No intrinsic hemostatic defect
14 207000 2 10.8 1.1 55.5 13.4 10.2 2.3 60.5 60.7 1.4 Factor Assay Mild Hemophilia A
16 160000 2.3 10.4 0.9 149 12.5 Factor Assay Severe Hemophilia A
3 326000 10.8 1 166 13.4 Factor Assay Severe Hemophilia A
2 280000 2.3 11 1 37.5 13 4.7 1.2 55.6 71 0 No intrinsic hemostatic defect
17 279000 3 57.1 5.2 54.3 13.4 9.2 2.8 54.2 67 0.4 Factor Assay Acquired bleeding disorder
4 403000 3 10.9 1 33.1 12.7 7.1 1.7 70.5 77.5 0 No intrinsic hemostatic defect
8 298000 2.3 11 1.2 48.6 14 7.5 2.1 60.7 67.7 0 Factor assay Mild Hemophilia A
0 183000 3 12.3 1.1 51.1 14.6 10.4 3.7 46.2 57.1 0 No Intrinsic hemostatic defect
3 290000 2.3 10.3 0.9 30.6 14.5 5.3 1.6 62 62.7 0.8 No intrinsic hemostatic defect
3 228000 2.3 10.7 0.9 80.7 14.2 13.9 3 50.6 60.1 0 Factor assay Moderate Hemophilia B  
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6 315000 15 10.3 0.9 39.2 13.2 13.3 3.8 42.8 61.3 0 Von willebrand Factor antigen assay Von Willebrand Disease Type 3
10 377000 11.7 1 121.5 13.8 44.2 10.8 23.7 60.5 0 Factor assay Severe Hemophilia B
17 286000 3.3 10.9 1 161.6 14.6 85.9 34.8 7 52.1 0 Factor Assay Severe Hemophilia A
2 196000 15 10.8 1 38.6 14.9 5.7 1.4 66.1 71.4 0 LTA Acquired bleeding disorder
4 298000 2.3 10.5 0.9 46.3 13.2 9.2 2.8 53.3 63.2 0 No intrinsic hemostatic defect
12 275000 8 10.8 1 88.8 14 8.5 3.1 43.1 65.6 0 Von willebrand Factor antigen assay Von Willebrand Disease Type 3
21 265000 2.3 11 1 157.6 14.5 24.8 7.2 28.7 66.1 0.3 Factor Assay Severe Hemophilia A
0 275000 2.3 10.3 0.9 41.5 13.8 6.2 2 46.4 62.4 0 No Intrinsic hemostatic defect
2 257000 3 11.4 1 30 13.5 6.8 6.4 67.8 67.8 0 No intrinsic hemostatic defect
0 267000 3.3 12.5 1.1 56.3 13.7 14.7 3.7 37.1 56.8 0 Factor Assay Mild Hemophilia A
2 392000 10.3 0.9 39.1 13.7 4.3 1.3 72.6 71 0 No intrinsic hemostatic defect
2 180000 4.3 10.9 1 36.1 13.9 6.9 1.7 67.6 71.1 0 No intrinsic hemostatic defect
19 217000 2.3 10.2 0.9 38 12.9 10.9 2.7 52.3 66.4 0 Factor assay Severe Hemophilia A
2 294000 3.3 11.6 1.1 41.6 14.4 7 2 56 66.2 0 No intrinsic hemostatic defect
19 185000 2.3 10.8 1 137 12.5 31.1 7.8 33.4 72 0 Factor Assay Severe Hemophilia A
22 177000 2.3 10.9 1 143.8 13.7 Factor Assay Severe Hemophilia A
26 316000 3 12.1 1.1 39.6 12.7 10.2 2.8 52.9 62.9 0 Factor Assay Factor V deficiency
3 195000 3 11.4 1 52.7 13.5 7.5 2.1 61.5 65.9 0 Factor Assay Severe Hemophilia A
11 180000 15 10.4 1 33.5 14.1 5.3 5 48.6 29.3 0 LTA/Flow cytometry Glanzmanns thrombosthenia
18 45000 8 11.1 1 40.4 13.7 6.5 2.3 63.4 63.5 0 LTA/Flow cytometry Bernnard Soulier Syndrome
17 302000 15 11 1 32.6 13.7 11.8 8.3 29.8 26.7 0 LTA/Flow cytometry Glanzmanns Thromosthenia
3 202000 3.3 10.9 1 45.2 13.8 6.8 1.7 65.7 60.9 0 No intrinsic hemostatic defect
13 433000 2.3 11.8 1 41.5 12.5 8.2 2.2 62.5 69.4 1.5 Factor Assay Factor XIII deficiency
9 266000 15 12.6 1.2 38.2 15.1 7.7 2.8 46.6 50.2 0 LTA/Flow cytometry Glanzmanns Thrombosthenia
6 290000 15 12 1.1 34.5 14.9 8.3 17.4 17 0 LTA/Flow cytometry Glazmanns Thrombesthenia
4 36000 5.3 11.2 1 40.4 13.8 6.3 2.8 51.4 61 0 LTA Von willebrand disease type 2B
12 309000 104.3 9.4 180 14.6 Factor Assay Severe Factor II deficiensy
10 332000 3.3 10.9 1 87.3 15 12.8 3.6 43 59.1 0 Factor Assay Mild Hemophilia A
20 320000 3 11.1 1 145.5 14.6 52.3 19.7 11.6 44 0 Factor assay Severe Hemophilia A
20 262000 3 15.6 1.4 36 26.1 7.7 5.9 32 27.5 31.7 Fibrimogen assay and activity Hypodysfibrinogenemia
0 435000 3 10.3 0.9 36.5 12.9 4.4 1.1 74.3 71.2 0.9 No intrinsic hemostatic defect
17 220000 15 26.9 2.5 54.8 13.2 8.3 1.5 66.8 74 0 LTA/Factor assay Severe Platelet dysfunction/Factor deficiency
11 223000 15 11.1 1 43.7 14 7.8 6.8 33.8 51.9 0 LTA/Flow Cytometry Glanzmanns Thrombosthenia
8 172000 10.9 1 43.4 13.2 4.5 1 71.5 68.2 0 Factor assay Acquired bleeding disorder
5 210000 12 1.1 38 12.3 9 6.9 34.9 24.9 0 LTA/Flow cytometry Glanzmanns Thrombasthenia
7 370000 2.3 104.4 9.4 180 12.9 49.2 35.8 31 0 Factor Assay Severe Factor X and mild Factor IX deficiency
3 13000 10.9 1 43.2 14.1 11.9 5.7 34.1 41.8 0 Acquired bleeding disorder
3 464000 11.6 1 75.2 12.4 14.9 2 58.9 69.7 0.8 Factor Assay Mild Hemophilia A
4 780000 11 1 44.7 14.1 6.3 1.5 68.4 67.5 2.2 No intrinsic hemostatic defect
4 177000 2.3 12.9 1.2 38.1 13.1 6.6 2.2 57.6 67.4 1 No intrinsic Hemostatic defect
5 186000 3 10.6 1 34.3 13 5.4 1.5 69.5 72.8 0 No intrinsic hemostatic defect
2 153000 8 10.9 1 42.1 14.3 9.5 2.2 60.2 63.3 0 Platelet aggregometry Acquired bleeding disorder
2 196000 10.7 1 33.7 14 6.1 1.8 64.3 66.7 2 Platelet aggregometry Acquired plateelet dysfunctin with eosinophilia
4 397000 3.3 10.6 1 32.8 13.3 4.8 1.2 73.3 71.8 0 No intrinsic hemostatic defect  
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4 60000 6 10.6 1 39.8 12.9 6.5 2.1 60.1 64.6 0 LTA Macrothrombocytopenia
2 306000 3.3 11.1 1 36.4 14.7 4.3 1.3 71 65.6 0.4 No intrinsic hemostatic defect
4 370761 4 10.9 1 35.8 13.6 3.7 1.3 71.2 68.8 0.1 No intrinsic hemostatic defect
32 261000 15 10.2 0.9 32.7 12.4 3.8 6.2 56.3 26.4 0 LTA/Flow Cytometry Glanzmann Thrombasthenia
2 97000 5 10.8 1 35.4 13 4.5 1.6 67.9 66.5 0 No intrinsic hemostatic defect
4 251000 2.3 10.6 0.9 28.5 13.5 2 2.6 51.6 70.8 0 No intrinsic hemostatic defect
3 369000 5 10.3 0.9 38.6 12.2 5.7 1.1 74.1 76.3 0 No intrinsic hemostatic defect
4 340000 15 12.6 1.2 104.9 13.7 8.8 2.3 60.9 61.6 0 Von Willebrand antigen assay Von Willebrand disease Type 3
13 219000 15 10.9 1 37.5 13.1 11.8 9.3 27.1 25.5 0 LTA/Flow Cytometry Glanzmann Thrombasthenia
19 47000 12 10.3 0.9 31.4 13.3 9.7 4.8 37 58.9 0 LTA/Flow Cytometry Bernard Soulier Syndrome
2 889000 15 11.4 1.1 40.1 12.1 6.3 1.9 60.1 37.4 0 LTA/Flow cytometry Glanzmann Thrombasthenia
9 177000 15 11 1 35.5 13.3 5.3 4.8 54.9 23.7 0 LTA/Flow Cytometry Glanzmann Thrombasthenia
6 248000 3.3 10.1 0.9 31.3 13.2 4.8 1.4 66.2 70.5 0 No intrinsic hemostatic defect
3 266000 2.3 10.9 0.9 36.6 13.5 7.3 2.2 54.8 62.8 0 No intrinsic hemostatic defect
4 228000 3.3 10.3 0.9 25 14.1 3.8 1.3 72 73.1 0 No intrinsic hemostatic defect
20 247000 15 11.1 1 93.5 14.6 10.5 2.3 52.6 62.6 0.3 Von Willebrand Factor Antigen Von Willebrand Disease Type 3
6 232000 10.7 1 42.1 14 6.9 10.6 37.1 23.8 0 LTA/Flow Cytometry Glanzmann Thromboasthenia
9 283000 2.3 10.8 1 33.6 14.4 5.7 1.8 61.6 66.7 0.1 No intrinsic hemostatic defect
4 494000 120 10 180 120 Fibrinogen antigen and activity Afibrinogenemia
4 190000 2.3 10.4 0.9 32.5 12.8 4.8 1.4 66.1 69.3 0 No intrinsic hemostatic defect
4 369000 46.6 4.3 133.7 13.5 9 1.3 73 75.2 0 Factor assay Severe Factor V deficiency
1 358000 3.3 10.4 0.9 35.3 13 5 1.5 69.5 59 1.3 No intrinsic  hemostatic defect
4 88000 6 12.1 1.1 133.1 13.9 14.3 3.8 44.2 59 0 LTA Acquired bleeding disorder
3 481000 18.9 1.7 70.1 14.9 8.8 2.1 62.2 63.3 0 Factor Assay Acquired bleeding disorder
31 18 3 10.4 1 145 13.3 86.7 32.1 9.6 68.9 0 Factor Assay Severe Hemophilia A
7 232000 3 10.6 0.9 36.1 13.7 5.3 1.5 67.7 70.9 0 No intrinsic henostatic defect
16 380000 2.3 11 1 37.7 11.2 6.2 2.1 63.6 73.4 0.8 Factor Assay Factor XIII deficiency
24 247000 2.3 10.5 1 152.1 12.1 89.4 35.8 7.8 Factor Assay Severe Hemophilia A`
0 180000 3 9.6 0.8 40 12 7.8 1.8 64.5 65.8 0 No intrinsic hemostatic defect
7 528000 10.7 1 151.9 12.9 27 10.3 21.6 57.2 0 Factor Assay Severe Hemophilia A
14 308000 3 11 1 151.8 13.1 31.5 13.3 19.3 72.6 0 Factor Assay Severe Hemophilia A
6 450000 12.4 1.1 154.5 15 20.7 5.5 36.4 66.5 0 Factor Assay Severe Hemophilia A
2 305000 3.3 10.6 0.9 31.7 14.5 3.3 0.9 75.1 72.4 2.3 No intrinsic hemostatic defect
4 236000 5.3 9.8 0.9 62.4 14.5 7.3 2.3 58.7 60.7 0 Factor Assay Mild Hemophilia A
2 339000 11.4 1 119.8 15 40 14.5 14.1 65.9 0 Factor Assay Severe Hemophilia A
6 11000 10.4 0.9 39.1 13.7 7.8 9.2 32 24.3 0 Acquired bleeding disorder
2 329000 2.3 12.1 1.1 42.2 14.7 2.4 1.3 72.4 70 0 No intrinsic hemostatic defect
5 236000 10.3 0.9 45.6 12.9 6.7 2.8 52.8 58.2 2.8 Factor Assay Factor XIII deficiency
3 261000 2.3 11.4 1.1 37.5 14.7 No intrinsic hemostatic defect
28 159000 2.3 10.9 0.9 119.3 14.4 10.2 37.5 7.2 48.9 0 Factor Assay Severe Hemophilia A
2 330000 2.3 10.8 1 36.8 14.7 7 44 5.5 46.8 0 No intrinsic hemostatic defect
6 404000 11.1 1 155.5 13.7 Factor Assay Severe Hemophilia A
18 275000 3 11.4 1.1 170.8 13.9 Factor Assay Severe Hemophilia B
5 398000 2.3 10.6 0.9 42.1 13.1 6.3 1.6 67.9 68.8 0 No Intrinsic hemostatic defect  
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8 326000 3.3 11 1 139.2 13.3 45 8.7 27.8 57.4 0 Factor Assay Severe Hemophilia A
2 525000 10.6 0.9 44.5 14.5 6.7 1.6 67.6 67.9 1.9 No Intrinsic hemostatic defect
4 236000 2.3 10.4 1 40 13.7 10.9 2.2 60 62.2 1.1 No intrinsic hemostatic defect
4 313000 10.1 0.9 29.4 12.6 6.5 1.2 73.5 76.7 0 No Intrinsic hemostatic defect
9 253000 3.3 120 10 180 120 Fibrinogen assay and activity Afibrinogenemia
3 208000 2.3 10.5 0.9 39.1 12.6 7.6 1.9 64 65.8 0 No Intrinsic hemostatic defect
4 447700 10.1 0.9 42.1 14.1 6.8 1.8 65.7 67.5 0.4 No intrinsic hemostatic defect
15 180000 15 10.7 0.9 29.5 12.3 7.5 28.7 19.8 0 LTA/Flow Cytometry Glanzzmann Thrombasthenia
3 130000 3.3 15.5 1.4 57.2 13.5 7.9 2.8 35.7 60 0 No Intrinsic hemostatic defect
0 297000 3 10.9 1 43.9 13.6 6.3 2.8 55.1 61 0 No Intrinsic Hemostatic defect
3 57000 15 10.9 1 33 13.2 5.8 1.4 75.2 77.2 0 Mild Macrothrombocytopenia/To r/o VWD Plt type
3 383000 3.3 10.1 0.9 28.4 14.1 4.3 1.1 73.7 74.9 0 No Intrinsic hemostatic defect
15 231000 3.3 10.5 0.9 151.6 13.1 15.9 5 36.6 74.6 0 Factor Assay Severe Hemophilia A
9 148000 3 12.6 1.2 35.2 13.4 4.7 1.3 72.3 72.9 0 Factor Assay Mild Factor VII deficiency
2 536000 10.8 1 39.6 13.1 6.1 2 62.4 64.3 0 No Intrinsic hemostatic defect
0 91000 9.3 10 0.9 30.1 12.7 7.4 2.1 59.2 65.8 0 No intrinsic hemostatic defect
3 532000 120 10 153.5 13.1 Fcator Assay Acquired bleeding disorder
16 411000 10.9 1 146 13.1 33.2 12.7 16.6 70.3 0 Factor Assay Severe Hemophilia A
0 302000 2.3 11.4 1 121.5 13.1 14.8 3.6 44.2 63.4 0 Factor Assay Exclude- Improper history
0 405000 11 1 127.1 14.1 15 2.7 56.7 69 0 Factor Assay Exclude- Improper history
2 181000 3 10.6 0.9 48.3 14.2 10.8 3.9 42.3 62.1 0 No Intrinsic hemostatic defect
3 194000 2.3 10.9 1 39.6 13 5 1.3 68.7 76.3 0.4 No Intrinsic hemostatic defect
2 222000 2.3 13 1.2 44.4 13.7 5 1.3 65.9 72.4 0 No Intrinsic hemostatic defect
6 224000 4 10.2 0.9 30.4 14.4 3.8 1.8 59.7 50.9 2.6 Factor assay Factor XIII deficiency
12 103000 2.3 14.7 1.4 107 13.6 20.1 8.3 24.4 43.6 0 Factor Assay Moderate Hemophilia A
2 290000 2.3 11.2 1.1 34.7 14.7 5.7 1.6 68.5 69.6 0.1 Von Willebrand Antigen/Ricof Von Willebrand Disease Type 2A/2M
2 154000 12.9 1.2 32.9 15.8 4 1.3 68.9 66.7 0.5 No Intrinsic Hemostatic defect
10 450000 120 10 35.7 13.4 7 1.3 71.5 72.3 1.1 Factor Assay Severe Factor VII deficiency
11 311000 2.3 11 1 142 13.9 49 14.2 14.5 49.4 0 Factor Assay Severe Hemophilia A
6 339000 11.3 1.1 154.2 14.4 60.9 15.7 14.8 55.6 0 Factor Assay Severe Hemophilia A
10 141000 3.3 10.3 0.9 32.4 13.8 6.4 1.7 62.7 73.7 0 No Intrinsic hemostatic defect
7 159000 15 10 0.9 68.4 13 11.5 2.7 53.7 61.3 0 Von Willebrand Factor Antigen Von Willebrand Disease Type 3
19 378000 2.3 11.9 1.1 150.2 13.5 35.8 8.5 26.4 49.1 0.6 Factor Assay Severe Hemophilia A
0 349000 10.9 1 68.3 13.6 6.2 1.1 74.5 71.4 0.9 No Intrinsic hemostatic defect
8 405000 11.1 1 43.7 13.1 8 1.8 67.3 64.9 2.5 LTA Acquired bleeding disorder
4 367000 3.3 9.3 0.9 30.1 11.7 3.8 1.3 67.6 72.5 0 No Intrinsic hemostatic defect
11 320000 2 10 0.9 96.7 12.6 8.2 2.3 61.4 60 0 Factor Assay Severe Hemophilia A
13 147000 4 10.7 1 151 12.8 40.8 23.4 5.8 42.3 0 Factor Assay Severe Hemophilia A
3 288000 3 9.8 0.9 30.3 12.3 4.7 1.3 72.5 74 0.1 No Intrinsic hemostatic defect
2 35000 3.5 10.9 1 33.1 14.1 8.5 3.2 43.9 52 0 Acquired bleeding disorder
3 397000 2.3 15.9 1.5 78.7 13.9 7.5 1.8 64.1 58 0.6 Factor assay Combined Factor Deficiency
6 268000 6 12.1 1.1 47.8 13.6 6.5 1.3 66 69.9 0.1 LTA Von Willebrand disease 2A/M
3 300000 2.3 10.3 1 35.7 13.6 7.4 1.9 57.4 64.1 0.3 No Intrinsic hemostatic defect
3 221000 3.3 12.4 1.5 40.1 14.9 7.4 3.1 50.6 56.6 0 LTA Acquired bleeding disorder  
2 307000 3 10.3 1 36.5 12.8 6.1 1.7 67.3 70 0 No intrinsic hemostatic defect
6 460000 11.7 1 180 12.7 11.7 1.7 68.4 72.8 0 Factor assay Severe Hemophilia A
6 298000 2.3 11.1 1 37.3 14.7 6.5 2.1 60.3 67.5 0 No Intrinsic hemostatic defect
6 369000 2.3 10.8 1 41.4 13.6 6.5 2.1 60.3 67.5 0 No Intrinsic hemostatic defect  
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